Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Gross Margin (2019 - 2025)

Coherus Oncology (CHRS) has disclosed Gross Margin for 7 consecutive years, with 68.27% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 383.0% to 68.27% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 67.24% through Dec 2025, up 31.0% year-over-year, with the annual reading at 67.24% for FY2025, 31.0% up from the prior year.
  • Gross Margin hit 68.27% in Q4 2025 for Coherus Oncology, up from 67.84% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 90.95% in Q1 2021 to a low of 7.6% in Q4 2023.
  • Historically, Gross Margin has averaged 63.17% across 5 years, with a median of 67.37% in 2025.
  • Biggest five-year swings in Gross Margin: plummeted -6108bps in 2023 and later soared 5684bps in 2024.
  • Year by year, Gross Margin stood at 83.5% in 2021, then fell by -18bps to 68.68% in 2022, then crashed by -89bps to 7.6% in 2023, then skyrocketed by 748bps to 64.44% in 2024, then rose by 6bps to 68.27% in 2025.
  • Business Quant data shows Gross Margin for CHRS at 68.27% in Q4 2025, 67.84% in Q3 2025, and 66.89% in Q2 2025.